
|Articles|November 22, 2021
Daily Medication Pearl: Tosymra (Sumatriptan Nasal Spray) for Migraine
Author(s)Saro Arakelians, PharmD
Tosymra is indicated for the acute treatment of migraine with or without aura in adults.
Advertisement
Medication Pearl of the Day: Tosymra (Sumatriptan Nasal Spray)
Indication: Tosymra is indicated for the acute treatment of migraine with or without aura in adults.
Insight:
- Dosing:The recommended dose of Tosymra is 10 mg given as a single spray in one nostril.
- Dosage form: Single-dose nasal spray device delivering 10 mg of sumatriptan.
- Adverse events: Myocardial ischemia, Prinzmetal’s angina, arrhythmias, cerebrovascular events, overuse headache, and seizures.
- Mechanism of action:Sumatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
- Manufacturer: Upsher-Smith
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Can Drive Equitable Diagnostics Access, Improve Antimicrobial Resistance Stewardship
2
From Stigma to Breakthrough: Psychedelic Medicine
3
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
4
How Pharmacy and Public Health Partner to Combat Infectious Diseases
5